nach oben

Drugs

Erschienen in:

01.02.2001 | Therapy in Practice

Treatment Options for Sleep Apnoea

verfasst von: Dr Ronald R. Grunstein, Jan Hedner, Ludger Grote

Erschienen in: Drugs | Ausgabe 2/2001

Einloggen, um Zugang zu erhalten

Abstract

Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality of life, driving accidents and probably represents a vascular disease risk factor. Currently, the most effective treatments are aimed at increasing upper airway space by either air pressure [(continuous positive airway pressure (CPAP)], upper airway surgery or oral appliances. CPAP is the main treatment modality for moderate to severe SA but noncompliance approaches 50% in clinic populations. A number of pharmacological agents have been used in SA but at this stage, none are indicated in moderate to severe SA.

Remmers JE, de Grott WJ, Sauerland EK, et al. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol 1978; 44: 931–8PubMed

Fleetham JA. Upper airway imaging in relation to obstructive sleep apnoea. Clin Chest Med 1992; 13: 399–416PubMed

Horner RL, Innes JA, Murphey K, et al. Evidence for reflex upper airway dilator muscle activation by sudden negative airway pressure in man. J Physiol 1991; 436: 15–29PubMed

Horner RL, Innes JA, Morrell MJ, et al. The effect of sleep on reflex genioglossus muscle activation by stimuli of negative airway pressure in humans. J Physiol 1994; 476(1): 141–51PubMed

Larsson H, Carlsson-Nordlander B, Lindblad LE, et al. Temperature thresholds in the oropharynx of patients with obstructive sleep apnoea syndrome. Am Rev Respir Dis 1992; 146 (5 Pt 1): 1246–9PubMed

Bradley TD, Phillipson EA. Central sleep apnoea. Clin Chest Med 1992; 13: 493–505PubMed

Strohl KP, Redline S. Recognition of obstructive sleep apnoea. Am J Respir Crit Care Med 1996; 154: 279–89PubMed

Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230–5PubMedCrossRef

Bearpark H, Elliott L, Grunstein R, et al. Snoring and sleep apnoea: a population study in Australian men. Am J Respir Crit Care Med 1995; 151: 1459–65PubMed

10.

Grunstein R, Wilcox I, Yang TS, et al. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int JObes 1993; 17: 533–40

11.

Grunstein RR, Stenlof K, Hedner J, et al. Impact of obstructive sleep apnoea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. Int J Obes 1995; 19: 410–8

12.

Brooks LJ, Strohl KP. Size and mechanical properties of the pharynx in healthy men and women. Am Rev Respir Dis 1992; 146(6): 1394–7PubMed

13.

Redline S, Tishler PV, Tosteson TD, et al. The familial aggregation of obstructive sleep apnoea. Am J Respir Crit Care Med 1995; 151: 682–7PubMed

14.

Wetter DW, Young TB, Bidwell TR, et al. Smoking as a risk factor for sleep-disordered breaming. Arch Intern Med 1994; 154: 2219–24PubMedCrossRef

15.

Grunstein RR, Ho KY, Sullivan CE. Sleep apnoea in acromegaly. Ann Intern Med 1991; 115: 527–32PubMed

16.

Working Group on OSA and Hypertension. Obstructive sleep apnoea and blood pressure elevation: what is the relationship? Blood Press 1993; 2(3): 166–82CrossRef

17.

Fletcher EC, Lesske J, Qian W, et al. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992; 19: 555–61PubMedCrossRef

18.

Brooks D, Horner RL, Kozar LF, et al. Obstructive sleep apnoea as a cause of systemic hypertension: evidence from a canine model [see comments]. J Clin Invest 1997; 99(1): 106–9PubMedCrossRef

19.

Hedner JA, Wilcox I, Laks L, et al. A specific and potent pressor effect of hypoxia in patients with sleep apnoea. Am Rev Respir Dis 1992; 146: 1240–5PubMed

20.

Hedner J, Ejnell H, Caidahl K. Left ventricular hypertrophy independent of hypertension in patients with obstructive sleep apnoea. J Hypertens 1990; 8: 941–6PubMedCrossRef

21.

Malone S, Liu PP, Holloway R, et al. Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure. Lancet 1991; 338: 1480–4PubMedCrossRef

22.

Laks L, Lehrhaft B, Grunstein RR, et al. Pulmonary hypertension in obstructive sleep apnoea. Eur Respir J 1995; 8: 537–41PubMed

23.

Carlson JT, Hedner JA, Ejnell H, et al. High prevalence of hypertension in sleep apnoea patients independent of obesity. Am J Respir Crit Care Med 1994; 150(1): 72–7PubMed

24.

Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breaming and hypertension. N Engl J Med 2000; 342(19): 1378–84PubMedCrossRef

25.

He J, Kryger MH, Zorick FJ, et al. Mortality and apnoea index in obstructive sleep apnoea: experience in 385 male patients. Chest 1988; 94: 9–14PubMedCrossRef

26.

Hung J, Whitford EG, Parsons RW, et al. Association of sleep apnoea with myocardial infarction in men. Lancet 1990; 336: 261–4PubMedCrossRef

27.

Palomaki H, Partinen M, Erkinjuntti T, et al. Snoring, sleep apnoea syndrome, and stroke. Neurology 1992; 42: 75–81PubMed

28.

Köhler U, Schäfer H. Is obstructive sleep apnoea (OSA) a risk factor for myocardial infarction and cardiac arrhythmias in patients with coronary heart disease (CHD)? Sleep 1996; 19: 283–6

29.

Peker Y, Hedner J, Johansson A, et al. Reduced hospitalization with cardiovascular and pulmonary disease in obstructive sleep apnoea patients on nasal CPAP treatment. Sleep 1997; 20(8): 645–53PubMed

30.

Quan SF, Howard BV, Iber C, et al. The sleep heart health study: design, rationale, and methods. Sleep 1997; 20(12): 1077–85PubMed

31.

Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnoea and the risk of traffic accidents: Cooperative Group Burgos-Santander [see comments]. N Engl J Med 1999; 340(11): 847–51PubMedCrossRef

32.

Braver HM, Block AJ, Perri MG. Treatment for snoring: combined weight loss, sleeping on side, and nasal spray. Chest 1995; 107: 1283–8PubMedCrossRef

33.

Series F, Roy N, Marc I. Effects of sleep deprivation and sleep fragmentation on upper airway collapsibility in normal subjects. Am J Respir Crit Care Med 1994; 150(2): 481–5PubMed

34.

Sullivan CE, Issa FG, Berthon-Jones M, et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981; I: 862–5CrossRef

35.

Grunstein RR. Sleep-related breathing disorders: 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea. Thorax 1995; 50(10): 1106–13

36.

Ballester E, Badia JR, Hernandez L, et al. Evidence of the effectiveness of continuous positive airway pressure in the treatment of sleep apnoea/hypopnea syndrome. Am J Respir Crit Care Med 1999; 159(2): 495–501PubMed

37.

Engleman HM, Kingshott RN, Wraith PK, et al. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnoea/Hypopnea syndrome. Am J Respir Crit Care Med 1999; 159(2): 461–7PubMed

38.

Berthon-Jones M. Feasibility of a self-setting CPAP machine. Sleep 1993; 16: S120–S3PubMed

39.

Meslier N, Lebrun T, Grillier-Lanoir V, et al. A French survey of 3,225 patients treated with CPAP for obstructive sleep apnoea: benefits, tolerance, compliance and quality of life. Eur Respir J 1998; 12(1): 185–92PubMedCrossRef

40.

Sanders MH, Kern N. Obstructive sleep apnoea treated by independently adjusted inspiratory and expiratory positive airway pressures via nasal mask: physiologic and clinical implications. Chest 1990; 98: 317–24PubMedCrossRef

41.

Schmidt-Nowara W, Lowe A, Wiegand L, et al. Oral appliances for the treatment of snoring and obstructive sleep apnoea: a review. Sleep 1995; 18(6): 501–10PubMed

42.

Miki H, Hida W, Chonan T, et al. Effects of submental electrical stimulation during sleep on upper airway patency in patients with obstructive sleep apnoea. Am Rev Respir Dis 1989; 140: 1285–9PubMedCrossRef

43.

Conradt R, Hochban W, Heitmann J, et al. Sleep fragmentation and daytime vigilance in patients with OSAtreated by surgical maxillomandibular advancement compared to CPAP therapy. J Sleep Res 1998; 7: 217–23PubMedCrossRef

44.

Fujita S, Conway W, Zorick F, et al. Surgical correction of anatomic abnormalities in obstructive sleep apnoea syndrome: uvulopalatopharyngoplasty. Otolaryngol Head Neck Surg 1981; 89: 923–34PubMed

45.

Rodenstein DO. Assessment of uvulopalatopharyngoplasty for the treatment of sleep apnoea syndrome. Sleep 1992; 15: S56–S62PubMed

46.

Walker EB, Frith RW, Harding DA, et al. Uvulopalatopharyngoplasty in severe idiopathic obstructive sleep apnoea syndrome. Thorax 1989; 44: 205–8PubMedCrossRef

47.

Sher AE. Update on upper airway surgery for obstructive sleep apnoea. Curr Opin Pulm Med 1995; 1: 504–11PubMedCrossRef

48.

Phillipson EA. Sleep apnoea: a major public health problem [editorial; comment]. N Engl J Med 1993; 328: 1271–3PubMedCrossRef

49.

Schmidt HS, Clark RW, Hyman PR. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977; 134(2): 183–5PubMed

50.

Brownell LG, West P, Sweatman P, et al. Protriptyline in obstructive sleep apnoea: a double-blind trial. N Engl J Med 1982; 307: 1037–42PubMedCrossRef

51.

Clark RW, Schmidt HS, Schaal SF, et al. Sleep apnoea: treatment with protriptyline. Neurology 1979; 29: 1287–92PubMedCrossRef

52.

Smith PL, Haponik EF, Allen RP, et al. The effects of protriptyline in sleep-disordered breaming. Am Rev Respir Dis 1983; 127: 8–13PubMed

53.

Nykamp K, Rosenthal L, Folkerts M, et al. The effects of REM sleep deprivation on the level of sleepiness/alertness. Sleep 1998; 21(6): 609–14PubMed

54.

Rubin AH, Alroy GG, Peled R, et al. Preliminary clinical experience with imipramine HCl in the treatment of sleep apnoea syndrome. Eur Neurol 1986; 25: 81–5PubMedCrossRef

55.

Meyer Madaus H, Haug HJ, Kessler C. Imipramine in sleep apnoea syndrome [in German]. Dtsch Med Wochenschr 1991; 116(45): 1734–5PubMed

56.

Schmidt HS. L-tryptophan in the treatment of impaired respiration in sleep. Bull Eur Physiopathol Respir 1983; 19: 625–9PubMed

57.

Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnoea to fluoxetine and protriptyline. Chest 1991; 100: 416–21PubMedCrossRef

58.

Kraiczi H, Hedner J, Dahlof P, et al. Effect of serotonin uptake inhibition on breaming during sleep and daytime symptoms in obstructive sleep apnoea. Sleep 1999; 22(1): 61–7PubMed

59.

Rose D, Khater-Boidin J, Toussaint P, et al. Central effects of 5-HT on respiratory and hypoglossal activities in the adult cat. Respir Physiol 1995; 101(1): 59–69PubMedCrossRef

60.

Veasey SC, Panckeri KA, Hoffman EA, et al. The effects of serotonin antagonists in an animal model of sleep-disordered breathing. Am J Respir Crit Care Med 1996; 153(2): 776–86PubMed

61.

Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. J Appl Physiol 1998; 84(3): 1055–62PubMed

62.

Cistulli PA, Barnes DJ, Grunstein RR, et al. Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax 1994; 49(7): 699–702PubMedCrossRef

63.

Stewart DA, Grunstein RR, Berthon-Jones M, et al. Androgen blockade does not affect sleep-disordered breaming or chemosensitivity in men with obstructive sleep apnoea. Am Rev Respir Dis 1992; 146: 1389–93PubMed

64.

Cook WR, Benich JJ, Wooten SA. Indices of severity of obstructive sleep apnoea syndrome do not change during medroxyprogesterone acetate therapy. Chest 1989; 96: 262–6PubMedCrossRef

65.

Rajagopal KR, Abbrecht PH, Jabbari B. Effects of medroxyprogesterone acetate in obstructive sleep apnoea. Chest 1986; 90: 815–21PubMedCrossRef

66.

Bayliss DA, Millhorn DE, Gallman EA, et al. Progesterone stimulates respiration through a central nervous system steroid receptor-mediated mechanism in cat. Proc Natl Acad Sci U S A 1987; 84(21): 7788–92PubMedCrossRef

67.

Hannhart B, Pickett CK, Moore LG. Effects of estrogen and progesterone on carotid body neural output responsiveness to hypoxia. J Appl Physiol 1990; 68(5): 1909–16PubMed

68.

Sutton Jr FD, Zwillich CW, Creagh CE, et al. Progesterone for outpatient treatment of Pickwickian syndrome. Ann Intern Med 1975; 83: 476–9PubMed

69.

Saaresranta T, Polo-Kantola P, Irjala K, et al. Respiratory insufficiency in postmenopausal women: sustained improvement of gas exchange with short-term medroxyprogesterone acetate. Chest 1999; 15: 1581–7CrossRef

70.

Grieger E, Schneider H, Weichler U, et al. Therapy control of theophylline evening dosage in patients with sleep-related respiratory disorders: follow-up study [in German]. Pneumologie 1993; 47 Suppl. 1: 166–9PubMed

71.

Kempf P, Mossinger B, Muller B, et al. Comparative studies on the effect of nasal CPAP, theophylline and oxygen in patients with sleep apnea syndrome [in German]. Pneumologie 1991; 45 Suppl. 1: 279–82PubMed

72.

Guilleminault C, Hayes B. Naloxone, theophylline, bromocriptine, and obstructive sleep apnoea: negative results. Bull Eur Physiopathol Respir 1983; 19: 632–4PubMed

73.

Espinoza H, Antic R, Thornton AT, et al. The effects of aminophylline on sleep and sleep-disordered breaming in patients with obstructive sleep apnoea syndrome. Am Rev Respir Dis 1987; 136: 80–4PubMedCrossRef

74.

Mulloy E, McNicholas WT. Theophylline in obstructive sleep apnoea: a double-blind evaluation. Chest 1992; 101(3): 753–7PubMedCrossRef

75.

Roehrs T, Merlotti L, Halpin D, et al. Effects of theophylline on nocturnal sleep and daytime sleepiness/alertness. Chest 1995; 108(2): 382–7PubMedCrossRef

76.

Schwartz AR, Rowley JA, O’Donnell C, et al. Effect of hypertension on upper airway function and sleep. J Sleep Res 1995; 4 Suppl. 1: 83–8PubMedCrossRef

77.

Wilson CR, Manchanda S, Crabtree D, et al. An induced blood pressure rise does not alter upper airway resistance in sleeping humans. J Appl Physiol 1998; 84(1): 269–76PubMed

78.

Carley DW, Trbovic SM, Radulovacki M. Hydralazine reduces elevated sleep apnoea index in spontaneously hypertensive (SHR) rats to equivalence with normotensive Wistar-Kyoto rats. Sleep 1996; 19(5): 363–6PubMed

79.

Weichler U, Herres Mayer B, Mayer J, et al. Influence of anti-hypertensive drug therapy on sleep pattern and sleep apnoea activity. Cardiology 1991; 78: 124–30PubMedCrossRef

80.

Issa FG. Effect of clonidine in obstructive sleep apnoea. Am Rev Respir Dis 1992; 145: 435–9PubMed

81.

Kantola I, Rauhala E, Erkinjuntti M, et al. Sleep disturbances in hypertension: a double-blind study between isradipine and metoprolol. J Cardiovasc Pharmacol 1991; 18 Suppl. 3: S41–S5PubMed

82.

Heitmann J, Grote L, Knaack L, et al. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnoea [in process citation]. Eur J Clin Pharmacol 1998; 54(9–10): 691–6PubMedCrossRef

83.

Gold AR, Schwartz AR, Bleecker ER, et al. The effect of chronic nocturnal oxygen administration upon sleep apnoea. Am Rev Respir Dis 1986; 134: 925–9PubMed

84.

Hudgel DW, Hendricks C, Dadley A. Alteration in obstructive apnoea pattern induced by changes in oxygen-and carbondioxide-inspired concentrations. Am Rev Respir Dis 1988; 138: 16–9PubMedCrossRef

85.

Gothe B, Strohl KP, Levin S, et al. Nicotine: a different approach to treatment of obstructive sleep apnoea. Chest 1985; 87: 11–7PubMedCrossRef

86.

Davila DG, Hurt RD, Offord KP, et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breaming in nonsmokers. Am J Respir Crit Care Med 1994; 150(2): 469–74PubMed

87.

Schönhofer B, Köhler D. Benzodiazepine receptor antagonist (flumazenil) does not affect sleep-related breaming disorders. Eur Respir J 1996; 9: 1816–20PubMedCrossRef

88.

Hedner J, Grunstein R, Eriksson B, et al. A double-blind, randomized trial of sabeluzole —a putative glutamate antagonist —in obstructive sleep apnea. Sleep 1996; 19(4): 287–9PubMed

89.

Arnulf I, Homeyer P, Garma L, et al. Modafinil in obstructive sleep apnoea-hypopnea syndrome: a pilot study in 6 patients. Respiration 1997; 64(2): 159–61PubMedCrossRef

90.

Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnoea in patients with acromegaly. Ann Intern Med 1994; 121: 478–83PubMed

91.

Rajagopal KR, Abbrecht PH, Derderian SS, et al. Obstructive sleep apnoea in hypothyroidism. Ann Intern Med 1984; 101: 491–4PubMed

92.

Orr WC, Males JI, Imes NK. Myxedema and obstructive sleep apnoea. Am J Med 1981; 70: 1061–6PubMedCrossRef

93.

Kapur VK, Koepsell TD, deMaube J, et al. Association of hypothyroidism and obstructive sleep apnoea. Am J Respir Crit Care Med 1998; 158 (5 Pt 1): 1379–83PubMed

94.

Grunstein RR, Sullivan CE. Sleep apnoea and hypothyroidism: mechanisms and management. Am J Med 1988; 85: 775–9PubMedCrossRef

95.

White DP, Zwillich CW, Pickett CK, et al. Central sleep apnoea: improvement with acetazolamide therapy. Arch Intern Med 1982; 142: 1816–9PubMedCrossRef

96.

Debacker WA, Verbraecken J, Willemen M, et al. Central apnoea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med 1995; 151: 87–91PubMed

97.

Verbraecken J, Willemen M, De Cock W, et al. Central sleep apnoea after interrupting long term acetazolamide therapy. Respir Physiol 1998; 112(1): 59–70PubMedCrossRef

98.

Javaheri S, Parker TJ, Wexler L, et al. Effect of theophylline on sleep-disordered breathing in heart failure [see comments]. N Engl J Med 1996; 335(8): 562–7PubMedCrossRef

99.

Naughton MT, Bradley TD. Sleep apnoea in congestive heart failure. Clin Chest Med 1998; 19(1): 99–113PubMedCrossRef

100.

Bonnet MH, Dexter JR, Arand DL. The effect of triazolam on arousal and respiration in central sleep apnoea patients. Sleep 1990; 13: 31–41PubMed

Titel: Treatment Options for Sleep Apnoea
verfasst von: Dr Ronald R. Grunstein
Jan Hedner
Ludger Grote
Publikationsdatum: 01.02.2001
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 2/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200161020-00007

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Treatment Options for Sleep Apnoea

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2001

Zafirlukast

Prophylaxis against Herpesvirus Infections in Transplant Recipients

Comparative Review of Topical Ophthalmic Antibacterial Preparations

Omalizumab

Omalizumab

Safety Profiles for the HMG-CoA Reductase Inhibitors